The negotiations with drugmakers are projected to save older adults $1.5 billion in out-of-pocket costs when the new prices go into effect in 2026.
  • Eliquis, a blood thinner from Bristol Myers Squibb and Pfizer: $231 negotiated price, down from $521 list price.
  • Xarelto, a blood thinner from Johnson & Johnson; $197 negotiated price, down from $517 list price.
  • Januvia, a diabetes drug from Merck: $113 negotiated price, down from $527 list price.
  • Jardiance, a diabetes drug from Boehringer Ingelheim and Eli Lilly: $197 negotiated price, down from $573 list price.
  • Enbrel, a rheumatoid arthritis drug from Amgen: $2,355 negotiated price, down from $7,106 list price.
  • Imbruvica, a drug for blood cancers from AbbVie and Johnson & Johnson: $9,319 negotiated price, down from $14,934 list price.
  • Farxiga, a drug for diabetes, heart failure and chronic kidney disease from AstraZeneca: $178 negotiated price, down from $556 list price.
  • Entresto, a heart failure drug from Novartis: $295 negotiated price, down from $628 list price.
  • Stelara, a drug for psoriasis and Crohn’s disease from J&J: $4,695 negotiated price, down from $13,836 list price.
  • Fiasp and NovoLog, diabetes drugs from Novo Nordisk: $119 negotiated price, down from $495 list price.

The new negotiated prices were compared to the 2023 list prices of the drugs.